Literature DB >> 19687467

Experience with electrolyte levels after craniotomy for pediatric brain tumors.

Jennifer R Madden1, Emily Dobyns, Michael Handler, Nicholas K Foreman.   

Abstract

Children with brain tumors routinely undergo craniotomies for tumor resections. Nurses and nurse practitioners are critical in closely monitoring these patients. Postoperatively, these children may develop inappropriate vasopressin secretion, cerebral salt wasting syndrome, or a combination of both. Inappropriate fluid and electrolyte administration may exacerbate symptoms. Both high and low sodium levels are associated with significant complications. Sodium levels were prospectively observed for 72 hours perioperatively. Overall, 36 patients had 201 serum sodium levels measured over the course of 1 year. Postoperatively, 79 (39%) of the sodium levels were <135 mEq/L or >145 mEq/L. Of these abnormal sodium levels, 3 (1%) were <125 mEq/L and 2 (1%) were >165 mEq/L. All the abnormal sodium levels occurred in patients with suprasellar or hypothalamic lesions. This study suggests that children with resections of suprasellar or hypothalamic tumors need specialist attention in postoperative management of fluid and electrolytes. The nurse is in the ideal role to monitor closely the pediatric brain tumor patient at high risk for abnormal sodium levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687467     DOI: 10.1177/1043454209340320

Source DB:  PubMed          Journal:  J Pediatr Oncol Nurs        ISSN: 1043-4542            Impact factor:   1.636


  2 in total

Review 1.  Renal salt-wasting syndrome in children with intracranial disorders.

Authors:  Alberto Bettinelli; Laura Longoni; Fabiana Tammaro; Pietro B Faré; Luca Garzoni; Mario G Bianchetti
Journal:  Pediatr Nephrol       Date:  2012-01-12       Impact factor: 3.714

2.  Hyponatremia with intracranial malignant tumor resection in children.

Authors:  Cydni Williams; Tamara D Simon; Jay Riva-Cambrin; Susan L Bratton
Journal:  J Neurosurg Pediatr       Date:  2012-05       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.